| BML-CR3115-0025 | 25 µl | 105.00 USD |  |
||
| BML-CR3115-0100 | 100 µl | 336.00 USD | |
||
| Do you need bulk/larger quantities? | |||||
| Alternative Name: | CYP1A1 |
| Host: | Sheep |
| Immunogen: | Synthetic peptide corresponding to a portion of C-terminal rat CYP1A1. |
| UniProt ID: | P00185 |
| Species reactivity: | Rat |
| Specificity: | Recognizes rat CYP1A1. Not suitable for use on human tissue. |
| Applications: | IHC (FS), IHC (PS), WB |
| Blocking Peptide: | For Blocking peptide see Prod. No. BML-CP0111. |
| Formulation: | Liquid. Serum containing 0.01% sodium azide. |
| Shipping: | Blue Ice |
| Long Term Storage: | -20°C |
| Scientific Background: | Members of the cytochrome P-450 1A (CYP1A) sub-family are induced by a range of polycyclic aromatic compounds such as benzpyrene, 3-methylcholanthrene (Prod. No. BML-GR239), and pro-carcinogenic heterocyclic aromatic amines. Such compounds have been reported to induce CYP1A1 in rat liver, human placenta and lung. A rare polymorphism of the CYP1A1 gene has been implicated in familial Parkinson's Disease (PD), whereas in the rat, CYP1A1 has been localized to the globus pallidus, but not to the substantia nigra where cell death associated with the pathology of PD occurs. |
| Regulatory Status: | RUO - Research Use Only |
3-Methylcholanthrene |
||||||
| Ah receptor ligand | ||||||
| 56-49-5, ≥93% (UPLC) | Print as PDF | ||||||
| BML-GR239-0010 | 10 mg | 85.00 USD | |
|||
| BML-GR239-0050 | 50 mg | 345.00 USD | |
|||
| Do you need bulk/larger quantities? | ||||||
Blocking peptide for Cytochrome P450 1A1 (rat) pAbs (Prod. No. BML-CR3110, BML-CR3115) |
||||||
| ≥95% | Print as PDF | ||||||
| BML-CP0111-0100 | 100 µg | 66.00 USD | |
|||
| Do you need bulk/larger quantities? | ||||||
